ThromboGenics re-submits

ThromboGenics re-submits

BLA with US FDA ThromboGenics has resubmitted a Biologics License Application (BLA) with the US Food and Drug Administration (FDA) for ocriplasmin intravitreal injection, 2.5 mg/mL, for the treatment of symptomatic vitreomacular adhesion (VMA) including macular hole. In February 2012, the FDA indicated that it intended to assign a Priority Review designation to the original BLA submission for the same indication filed in December 2011. A company spokeswoman said the re-submission will allow ThromboGenics to meet the FDA's Priority Review timelines and to manage the phasing of its resources to support both its European and US ocriplasmin filings.

www.thrombogenics.com

Latest Articles
Beyond the Numbers

Empowering patient participation fosters continuous innovation in cataract surgery.

Read more...

Thinking Beyond the Surgery Room

Practice management workshop focuses on financial operations and AI business applications.

Read more...

Picture This: Photo Contest Winners

ESCRS 2025 Refractive and Cataract Photo Contest winners.

Read more...

Aid Cuts Threaten Global Eye Care Progress

USAID closure leads retreat in development assistance.

Read more...

Supplement: ESCRS Clinical Trends Series: Presbyopia

Read more...

Nutrition and the Eye: A Recipe for Success

A look at the evidence for tasty ways of lowering risks and improving ocular health.

Read more...

New Award to Encourage Research into Sustainable Practices

Read more...

Sharing a Vision for the Future

ESCRS leaders update Trieste conference on ESCRS initiatives.

Read more...

Extending Depth of Satisfaction

The ESCRS Eye Journal Club discuss a new study reviewing the causes and management of dissatisfaction after implantation of an EDOF IOL.

Read more...

Conventional Versus Laser-Assisted Cataract Surgery

Evidence favours conventional technique in most cases.

Read more...